Inhibition of RET activated pathways: Novel strategies for therapeutic intervention in human cancers

Current Pharmaceutical Design

Volumn 19, Issue 5, 2013, Pages 864-882

  Santarpia, Libero ^a   Bottai, Giulia ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

Cancer; Clinical trials; RET interacting proteins; RET proto oncogene; RET activated signalling pathways; Targeted therapies; Therapeutic strategies; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; CABOZANTINIB; CEP 751; FOSTAMATINIB; GELDANAMYCIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HERBIMYCIN A; IMATINIB; LESTAURTINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 7; MOTESANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE B; PROTEIN RET; SEMAXANIB; SIM 010603; SORAFENIB; STAUROSPORINE; SUNITINIB; TANESPIMYCIN; TOZASERTIB; UNCLASSIFIED DRUG; VANDETANIB; WITHAFERIN A;

ABDOMINAL PAIN; ADRENAL CANCER; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; CANCER GENETICS; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DIARRHEA; DISTANT METASTASIS; FATIGUE; GALLBLADDER CANCER; GASTROINTESTINAL CARCINOMA; GENE MUTATION; GENE REARRANGEMENT; GENETIC DISORDER; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LONG TERM CARE; LUNG CANCER; LUNG CARCINOMA; LYMPH VESSEL METASTASIS; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NAUSEA; NEOPLASM; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RASH; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH CANCER; THYROID CANCER; THYROID MEDULLARY CARCINOMA; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; WEIGHT REDUCTION;

EID: 84876726843     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804547240     Document Type: Article

References (274)

1. Pachnis V, Mankoo B, Costantini F. Expression of the c-ret protooncogene during mouse embryogenesis. Development 1993; 19: 1005-17.
2. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994; 367: 380-3.
3. Durbec PL, Larsson-Blomberg LB, Schuchardt A, Costantini F, Pachnis V. Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts. Development 1996; 122: 349-58.
4. Meng X, Lindahl M, Hyvönen ME, et al. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. Science 2000; 287: 1489-93.
5. Jain S, Naughton CK, Yang M, et al. Mice expressing a dominantnegative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis. Development 2004; 131: 5503-13.
6. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990; 60: 557-63.
7. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET protooncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851-6.
8. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-60.
9. Carlson KM, Dou S, Chi D, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 1994; 91: 1579-83.
10. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367: 375-6.
11. Boulay A, Breuleux M, Stephan C, et al. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer. Cancer Res 2008; 68: 3743-51.
12. Unger K, Wienberg J, Riches A, et al. Novel gene rearrangements in transformed breast cells identified by high-resolution breakpoint analysis of chromosomal aberrations. Endocr Relat Cancer 2010; 17: 87-98.
13. Esseghir S, Todd SK, Hunt T, et al. A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer. Cancer Res 2007; 67: 11732-41.
14. Plaza-Menacho I, Morandi A, Robertson D, et al. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene. 2010 Aug 19; 29: 4648-57.
15. Futami H, Sakai R. RET protein promotes non-adherent growth of NB-39-nu neuroblastoma cell line. Cancer Sci 2009; 100: 1034-9.
16. Esposito CL, D'Alessio A, de Franciscis V, Cerchia L. A cross-talk between TrkB and Ret tyrosine kinases receptors mediates neuroblastoma cells differentiation. PLoS One 2008; 3: e1643.
17. Peterson S, Bogenmann E. The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation. Oncogene 2004; 23: 213-25.
18. Dawson DM, Lawrence EG, MacLennan GT, et al. Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst 1998; 90: 519-23.
19. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012; 18: 375-7.
20. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18: 378-81.
21. Tanizaki J, Okamoto I, Sakai K, Nakagawa K. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer 2011; 105: 807-13.
22. Gimm O, Gössling A, Marsh DJ, et al. Mutation and deletion analysis of GFR alpha-1, encoding the co-receptor for the GDNF/RET complex, in human brain tumors. Br J Cancer 1999; 80: 383-6.
23. Wiesenhofer B, Stockhammer G, Kostron H, Maier H, Hinterhuber H, Humpel C. Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-alpha 1) are strongly expressed in human gliomas. Acta Neuropathol 2000; 99: 131-7.
24. Okada Y, Takeyama H, Sato M, et al. Experimental implication of celiac ganglionotropic invasion of pancreatic-cancer cells bearing c-ret proto-oncogene with reference to glial-cell-line-derived neurotrophic factor (GDNF). Int J Cancer 1999; 81: 67-73.
25. Gil Z, Cavel O, Kelly K, et al. Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J Natl Cancer Inst 2010; 102: 107-18.
26. Zeng Q, Cheng Y, Zhu Q, et al. The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J Int Med Res 2008; 36: 656-64.
27. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985; 42: 581-8.
28. Ishizaka Y, Itoh F, Tahira T, et al. Human RET proto-oncogene mapped to chromosome 10q11.2. Oncogene 1989; 4: 1519-21.
29. Hahn M, Bishop J. Expression pattern of Drosophila ret suggests a common ancestral origin between the metamorphosis precursors in insect endoderm and the vertebrate enteric neurons. Proc Natl Acad Sci USA 2001; 98: 1053-8.
30. Ponder BA. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res 1999; 59: 1736s-41s.
31. Takahashi M, Buma Y, Taniguchi M. Identification of the ret protooncogene products in neuroblastoma and leukemia cells. Oncogene 1991; 6: 297-301.
32. Takahashi M, Asai N, Iwashita T, Isomura T, Miyazaki K, Matsuyama M. Characterization of the ret proto-oncogene products expressed in mouse L cells. Oncogene 1993; 8: 2925-9.
33. Myers SM, Eng C, Ponder BA, Mulligan LM. Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: A novel C-terminus for RET. Oncogene 1995; 11: 2039-45.
34. de Graaff E, Srinivas S, Kilkenny C, et al. Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev 2001; 15: 2433-44.
35. Tsui-Pierchala BA, Ahrens RC, Crowder RJ, Milbrandt J, Johnson EM Jr. The long and short isoforms of Ret function as independent signaling complexes. J Biol Chem 2002; 277: 34618-25.
36. Degl'Innocenti D, Arighi E, Popsueva A, et al. Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching. Oncogene 2004; 23: 7297-309.
37. Schuetz G, Rosario M, Grimm J, Boeckers TM, Gundelfinger ED, Birchmeier W. The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells. J Cell Biol 2004; 167: 945-52.
38. Trupp M, Arenas E, Fainzilber M, et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 1996; 381: 785-9.
39. Durbec P, Marcos-Gutierrez CV, Kilkenny C, et al. GDNF signalling through the Ret receptor tyrosine kinase. Nature 1996; 381: 789-93.
40. Kotzbauer PT, Lampe PA, Heuckeroth RO, et al. Neurturin, a relative of glialcell-line-derived neurotrophic factor. Nature 1996; 384: 467-70.
41. Baloh RH, Tansey MG, Lampe PA, et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 1998; 21: 1291-302.
42. Milbrandt J, de Sauvage FJ, Fahrner TJ, et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 1998; 20: 245-53.
43. Jing S, Wen D, Yu Y, et al. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 1996; 85: 1113-24.
44. Baloh RH, Enomoto H, Johnson Jr. EM, Milbrandt J. The GDNF family ligands and receptors-implications for neural development. Curr Opin Neurobiol 2000; 10: 103-10.
45. Treanor JJ, Goodman L, de Sauvage F, et al. Characterization of a multicomponent receptor for GDNF. Nature 1996; 382: 80-3.
46. Sanicola M, Hession C, Worley D, et al. Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins. Proc Natl Acad Sci USA 1997; 94: 6238-43.
47. Sariola H, Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci 2003; 116: 3855-62.
48. Paratcha G, Ledda F, Baars L, et al. Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts. Neuron 2001; 29: 171-84.
49. Tsui-Pierchala BA, Encinas M, Milbrandt J, Johnson Jr. EM. Lipid rafts in neuronal signaling and function. Trends Neurosci 2002; 25: 412-7.
50. Barnett MW, Fisher CE, Perona-Wright G, Davies JA. Signalling by glial cell line-derived neurotrophic factor (GDNF) requires heparan sulphate glycosaminoglycan. J Cell Sci 2002; 115: 4495-503.
51. van Weering DH, Medema JP, van Puijenbroek A, Burgering BM, Baas PD, Bos JL. Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells. Oncogene 1995; 11: 2207-14.
52. Worby CA, Vega QC, Zhao Y, Chao HH, Seasholtz AF, Dixon JE. Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase. J Biol Chem 1996; 271: 23619-22.
53. van Weering DH, Bos JL. Glial cell line-derived neurotrophic factor induces Ret-mediated lamellipodia formation. J Biol Chem 1997; 272: 249-54.
54. Segouffin-Cariou C, Billaud M. Transforming ability of MEN 2ARET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000; 275: 3568-76.
55. Borrello MG, Alberti L, Arighi E, et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol 1996; 16: 2151-63.
56. Chiariello M, Visconti R, Carlomagno F, et al. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene 1998; 16: 2435-45.
57. Kurokawa K, Kawai K, Hashimoto M, Ito Y, Takahashi M. Cell signalling and gene expression mediated by RET tyrosine kinase. J Intern Med 2003; 253: 627-33.
58. Hayashi Y, Iwashita T, Murakamai H, et al. Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN 2A mutation. Biochem Biophys Res Commun 2001; 281: 682-9.
59. Coulpier M, Anders J, Ibañez CF. Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival. J Biol Chem 2002; 277: 1991-9.
60. Liu X, Vega QC, Decker RA, Pandey A, Worby CA, Dixon JE. Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. J Biol Chem 1996; 271: 5309-12.
61. Salvatore D, Barone MV, Salvatore G, et al. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. J Clin Endocrinol Metab 2000; 85: 3898-907.
62. Pandey A, Duan H, Di Fiore PP, Dixit VM. The Ret receptor protein tyrosine kinase associates with the SH2-containing adapter protein Grb10. J Biol Chem 1995; 270: 21461-3.
63. Pandey A, Liu X, Dixon JE, Di Fiore PP, Dixit VM. Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7. J Biol Chem 1996; 271: 10607-10.
64. Alberti L, Borrello MG, Ghizzoni S, Torriti F, Rizzetti MG, Pierotti MA. Grb2 binding to the different isoforms of Ret tyrosine kinase. Oncogene 1998; 17: 1079-87.
65. Iwashita T, Asai N, Murakami H, Matsuyama M, Takahashi M. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN 2A or MEN 2B mutation. Oncogene 1996; 12: 481-7.
66. Encinas M, Tansey MG, Tsui-Pierchala BA, Comella JX, Milbrandt J, Johnson EM Jr. c-Src is required for glial cell line-derived neurotrophic factor (GDNF) family ligandmediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway. J Neurosci 2001; 21: 1464-72.
67. Zhang Y, Zhu W, Wang YG, et al. Interaction of SH2-Bbeta with RET is involved in signaling of GDNF-induced neurite outgrowth. J Cell Sci 2006; 119: 1666-76.
68. Arighi E, Alberti L, Torriti F, et al. Identification of Shc docking site on Ret tyrosine kinase. Oncogene 1997; 14: 773-82.
69. Lorenzo MJ, Gish GD, Houghton C, et al. REt alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2. Oncogene 1997; 14: 763-71.
70. Pelicci G, Troglio F, Bodini A, et al. The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 2002; 22: 7351-63.
71. Kurokawa K, Iwashita T, Murakami H, Hayashi H, Kawai K, Takahashi M. Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction. Oncogene 2001; 20: 1929-38.
72. Melillo RM, Carlomagno F, De Vita G, et al. The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. Oncogene 2001; 20: 209-18.
73. Murakami H, Yamamura Y, Shimono Y, Kawai K, Kurokawa K, Takahashi M. Role of Dok1 in cell signaling mediated by RET tyrosine kinase. J Biol Chem 2002; 277: 32781-90.
74. Grimm J, Sachs M, Britsch S, et al. Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation. J Cell Biol 2001; 154: 345-54.
75. Crowder RJ, Enomoto H, Yang M, Johnson Jr. EM, Milbrandt J. Dok-6, a novel p62 Dok family member, promotes Ret-mediated neurite outgrowth. J Biol Chem 2004; 279: 42072-81.
76. Durick K, Gill GN, Taylor SS. Shc and Enigma are both required for mitogenic signalling by Ret/ptc2. Mol Cell Biol 1998; 18: 229-308.
77. Andreozzi F, Melillo RM, Carlomagno F, et al. Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase. Oncogene 2003; 22: 2942-9.
78. Hayashi H, Ichihara M, Iwashita T et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 2000; 19: 446-75.
79. Jijiwa M, Fukuda T, Kawai K, et al. A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia. Mol Cell Biol 2004; 24: 8026-36.
80. Wong A, Bogni S, Kotka P, et al. Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform. Mol Cell Biol 2005; 25: 9661-73.
81. Mercalli E, Ghizzoni S, Arighi E, et al. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein. Oncogene 2001; 20: 3475-85.
82. De Falco V, Castellone MD, De Vita G, et al. RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. Cancer Res. 2007; 67: 381-90.
83. Soler RM, Dolcet X, Encinas M, Egea J, Bayascas JR, Comella JX. Receptors of the glial cell line-derived neurotrophic factor family of neurotrophic factors signal cell survival through the phosphatidylinositol 3-kinase pathway in spinal cord motoneurons. J Neurosci 1999; 19: 9160-9.
84. De Falco V, Guarino V, Malorni L, et al. RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors. Oncogene 2005; 24: 6303-13.
85. O'Bryan JP, Songyang Z, Cantley L, Der CJ, Pawson T. A mammalian adaptor protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain. Proc Natl Acad Sci U SA 1996; 93: 2729-34.
86. Pelicci G, Dente L, De Giuseppe A, et al. A family of Shc related proteins with conserved PTB, CH1 and SH2 regions. Oncogene 1996; 13: 633-41.
87. Carpino N, Wisniewski D, Strife A, et al. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 1997; 88: 197-204.
88. Yamanashi Y, Baltimore D. Identification of the Abl-and rasGAPassociated 62 kDa protein as a docking protein, Dok. Cell 1997; 88: 205-11.
89. Kashige N, Carpino N, Kobayashi R. Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity. Proc Natl Acad Sci USA 2000; 97: 2093-8.
90. Cai D, Dhe-Paganon S, Melendez PA, Lee J, Shoelson SE. Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5. J Biol Chem 2003; 278: 25323-30.
91. Uchida M, Enomoto A, Fukuda T, et al. Dok-4 regulates GDNFdependent neurite outgrowth through downstream activation of Rap1 and mitogen-activated protein kinase. J Cell Sci 2006; 119: 3067-77.
92. Bedirian A, Baldwin C, Abe J, Takano T, Lemay S. Pleckstrin homology and phosphotyrosine-binding domain-dependent membrane association and tyrosine phosphorylation of Dok-4, an inhibitory adapter molecule expressed in epithelial cells. J Biol Chem 2004; 279: 19335-49.
93. Kurotsuchi A, Murakumo Y, Jijiwa M, et al. Analysis of DOK-6 function in downstream signaling of RET in human neuroblastoma cells. Cancer Sci 2010; 101: 1147-55.
94. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-7.
95. Durick K, Wu RY, Gill GN, Taylor SS. Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain. J Biol Chem 1996; 271: 12691-4.
96. Guy PM, Kenny DA, Gill GN. The PDZ domain of the LIM protein enigma binds to b-tropomyosin,. Mol Biol Cell 1999; 10: 1973-84.
97. Zhou Q, Ruiz-Lozano P, Martone ME, Chen J. Cypher, a striated muscle-restricted PDZ and LIM domain-containing protein, binds to a-actinin-2 and protein kinase C. J Biol Chem 1999; 274: 19807-13.
98. Fukuda T, Kiuchi K, Takahashi M. Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase. J Biol Chem 2002; 277: 19114-21.
99. Kawamoto Y, Takeda K, Okuno Y, et al. Identification of RET autophosphorylation sites by mass spectrometry. J Biol Chem 2004; 279: 14213-24.
100. Watanabe T, Ichihara M, Hashimoto M, et al. Characterization of gene expression induced by RET with MEN 2A or MEN 2B mutation. Am J Pathol 2002; 161: 249-56.
101. Jain S, Watson MA, DeBenedetti MK, Hiraki Y, Moley JF, Milbrandt J. Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. Cancer Res 2004; 64: 3907-13.
102. Pierotti MA, Bongarzone I, Borello MG, Greco A, Pilotti S, Sozzi G. Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes Cancer 1996; 16: 1-14.
103. Jhiang SM. The RET proto-oncogene in human cancers. Oncogene 2000; 19: 5590-7.
104. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 1989; 63: 908-11.
105. Rosai J, Carcangiu ML, DeLellis RA. Atlas of tumor pathology. Tumors of the thyroid gland, 3rd series. Fascicle 5. Washington, DC: Armed Forces Institute of Pathology; 1992.
106. Pierotti MA, Santoro M, Jenkins RB, et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci USA 1992; 89: 1616-20.
107. Bongarzone I, Monzini N, Borrello MG, et al. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A. Mol Cell Biol 1993; 13: 358-66.
108. Santoro M, Dathan NA, Berlingieri MT, et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994; 9: 509-16.
109. Fugazzola L, Pierotti MA, Vigano E, Pacini F, Vorontsova TV, Bongarzone I. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. Oncogene 1995; 13: 1093-7.
110. Klugbauer S, Demidchik EP, Lengfelder E, Rabes HM. Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. Cancer Res 1998; 58: 198-203.
111. Rabes HM, Klugbauer S. Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement. Recent Results Cancer Res1998; 154: 248-64.
112. Klugbauer S, Rabes HM. The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene 1999; 18: 4388-93.
113. Salassidis K, Bruch J, Zitzelsberger H, Lengfelder E, Kellerer AM, Bauchinger M. Translocation t(10; 14)(q11.2: q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma. Cancer Res 2000; 60: 2786-9.
114. Klugbauer S, Jauch A, Lengfelder E, Demidchik E, Rabes HM. A novel type of RET rearrangement (PTC8) in childhood papillary thyroid carcinomas and characterization of the involved gene (RFG8). Cancer Res 2000; 60: 7028-32.
115. Corvi R, Berger N, Balczon R, Romeo G. RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma. Oncogene 2000; 19: 4236-42.
116. Nakata T, Kitamura Y, Shimizu K, et al. Fusion of a novel gene, ELKS, to RET due to translocation t(10; 12)(q11; p13) in a papillary thyroid carcinoma. Genes Chromosomes Cancer 1999; 25: 97-103.
117. Saenko V, Rogounovitch T, Shimizu-Yoshida Y, et al. Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient. Mutat Res 2003; 527: 81-90.
118. Ciampi R, Giordano TJ, Wikenheiser-Brokamp K, Koenig RJ, Nikiforov YE. HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr Relat Cancer 2007; 14: 445-52.
119. Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann NY Acad Sci 2002; 963: 116-21.
120. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000; 26: 89-92.
121. Kirschner LS, Kusewitt DF, Matyakhina L, et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res 2005; 65: 4506-14.
122. Sandrini F, Matyakhina L, Sarlis NJ, et al. Regulatory subunit type I-alpha of protein kinase A (PRKAR1A): a tumor-suppressor gene for sporadic thyroid cancer. Genes Chromosomes Cancer 2002; 35: 182-92.
123. Wang Y, Liu X, Biederer T, Südhof TC. A family of RIM-binding proteins regulated by alternative splicing: Implications for the genesis of synaptic active zones. Proc Natl Acad Sci USA 2002; 99: 14464-9.
124. Ducut Sigala JL, Bottero V, Young DB, et al. Activation of transcription factor NF-kappaB requires ELKS, an IkappaB kinase regulatory subunit. Science 2004; 304: 1963-7.
125. Wu ZH, Shi Y, Tibbetts RS, et al. Molecular linkage between the kinase ATM and NFkappaB signaling in response to genotoxic stimuli. Science 2006; 311: 1141-6.
126. Celetti A, Cerrato A, Merolla F, Vitagliano D, Vecchio G, Grieco M. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene 2004; 23: 109-21.
127. Merolla F, Pentimalli F, Pacelli R, et al. Involvement of H4(D10S170) protein in ATMdependent response to DNA damage. Oncogene 2007; 26: 6167-75.
128. Dupont S, Zacchigna L, Cordenonsi M, et al. Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell 2005; 121: 87-99.
129. He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massagué J. Hematopoiesis controlled by distinct TIF1-gamma and Smad4 branches of the TGFbeta pathway. Cell 2006; 125: 929-41.
130. Dho SH, Kwon KS. The Ret finger protein induces apoptosis via its RING finger-B box-coiled-coil motif. J Biol Chem 2003; 278: 31902-8.
131. Shimono Y, Murakami H, Hasegawa Y, Takahashi M. RET finger protein is a transcriptional repressor and interacts with enhancer of polycomb that has dual transcriptional functions. J Biol Chem 2000; 275: 39411-9.
132. Krützfeldt M, Ellis M, Weekes DB, et al. Selective ablation of retinoblastoma protein function by the RET finger protein. Mol Cell 2005; 18: 213-24.
133. Portella G, Salvatore D, Botti G, et al. Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene. Oncogene 1996; 13: 2021-6.
134. Wang C, Mayer JA, Mazumdar A, Brown PH. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells. Breast Cancer Res Treat 2011; 133: 487-500.
135. Flavin R, Jackl G, Finn S, et al. RET/PTC rearrangement occurring in primary peritoneal carcinoma. Int J Surg Pathol 2009; 17: 187-97.
136. Li F, Feng Y, Fang R, et al. Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. Cell Res 2012; 22: 928-31.
137. Schwaller J, Anastasiadou E, Cain D, et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5; 10)(q33; q22). Blood 2001; 97: 3910-8.
138. Puxeddu E, Zhao G, Stringer JR, Medvedovic M, Moretti S, Fagin JA. Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens. Mutat Res 2005; 570: 17-32.
139. Reiter A, Walz C, Watmore A, et al. The t(8; 9)(p22; p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65: 2662-7.
140. Zhong S, Delva L, Rachez C, et al. A RA-dependent, tumor-growth suppressive transcription complex is the target of the PMLRARalpha and T18 oncoproteins. Nat Genet 1999; 23: 287-95.
141. Belloni E, Trubia M, Gasparini P, et al. 8p11 myeloproliferative syndrome with a novel t(7; 8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes Chromosomes Cancer 2005; 42: 320-5.
142. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012; 18: 382-4.
143. Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012; 22: 436-45.
144. Ballerini P, Struski S, Cresson C, et al. RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. Leukemia 2012. Available from: http: //www.nature.com/leu/journal/vaop/ncurrent/pdf/leu2012109a.pdf.
145. Mak YF, Ponder BA. RET oncogene. Curr Opin Genet Dev 1996; 6: 82-6.
146. Romeo G, Ronchetto P, Luo YI, et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 1994; 367: 377-8.
147. Edery P, Lyonnet S, Mulligan LM, et al. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994; 367: 378-80.
148. Angrist M, Bolk S, Thiel B, et al. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum Mol Genet 1995; 4: 821-30.
149. Carlomagno F, De Vita G, Berlingieri MT, et al. Molecular heterogeneity of RET loss of function in Hirschsprung's disease. EMBO J 1996; 15: 2717-25.
150. Iwashita T, Murakami H, Asai N, Takahashi M. Mechanism of Ret dysfunction by Hirschsprung mutations affecting its extracellular domain. Hum Mol Genet 1996; 5: 1578-80.
151. Geneste O, Bidaud C, De Vita G, et al. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effector to a multifunctional docking site. Hum Mol Genet 1999; 8: 1989-99.
152. Lin L-FH, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130-2.
153. Pasini B, Borrello MG, Greco A, et al. Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet 1995; 10: 35-40.
154. Pelet A, Geneste O, Edery P, et al. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease. J Clin Invest 1998; 101: 1415-23.
155. Iwashita T, Kurokawa K, Qiao S, et al. Functional analysis of RET with Hirschsprung's mutations affecting the extracellular domain. Gastroenterology 2001; 121: 24-33.
156. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995; 15: 1613-9.
157. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995; 267: 381-3.
158. Borrello MG, Smith DP, Pasini B, et al. RET activation by germline MEN2A and MEN2B mutations. Oncogene 1995; 11: 2419-27.
159. Songyanag Z, Carraway IIIKL, Eck MJ, et al. Catalytic specificity of proteintyrosine kinase is critical for selective signalling. Nature 1995; 373: 536-9.
160. Bocciardi R, Mograbi B, Pasini B, et al. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 1997; 15: 2257-65.
161. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. J Am Med Assoc 1996; 276: 1575-9.
162. Frank-Raue K, Hoppner W, Frilling A, et al. Mutations of the RET protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. J Clin Endocrinol Metab 1996; 81: 1780-3.
163. Hoppner W, Ritter MM. A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet 1997; 6: 587-90.
164. Tessitore A, Sinisi AA, Pasquali D, et al. A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene. J Clin Endocrinol Metab 1999; 84: 3522-7.
165. Huang SC, Koch CA, Vortmeyer AO, et al. Duplication of the mutant REt allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Res 2000; 60: 6223-6.
166. Koch CA, Huang SC, Moley JF, et al. Allelic imbalance of the mutant and wild-type REt allele in MEN 2Aassociated medullary thyroid carcinoma. Oncogene 2001; 20: 7809-11.
167. Koch CA. Molecular pathogenesis of MEN2-associated tumors. Fam Cancer 2005; 4: 3-7.
168. Carlson KM, Bracamontes J, Jackson CE, et al. Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 1994; 55: 1076-82.
169. Marengere LE, Songyang Z, Gish GD, et al. SH2 domain specificity and activity modified by a single residue. Nature 1994; 369: 502-5.
170. Gimm O, Marsh DJ, Andrew SD, et al. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 1997; 82: 3902-4.
171. Smith DP, Houghton C, Ponder BA. Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 1997; 15: 1213-7.
172. Menko FH, van der Luijt RB, de Valk, et al. Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J Clin Endocrinol Metab 2002; 87: 393-7.
173. Miyauchi A, Futami H, Hai N, et al. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn. J. Cancer Res 1999; 90: 1-5.
174. Koch CA, Huang SC, et al. A patient with MEN 2 and multiple mutations of RET in the germline. Exp Clin Endocrinol Diabetes 2000; 108: 493.
175. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994; 6: 70-4.
176. Hofstra RM, Fattoruso O, Quadro L, et al. A novel point mutation in the intracellular domain of the RET protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 1997; 82: 4176-8.
177. Bolino A, Schuffenecker I, Luo Y, et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995; 10: 2415-9.
178. Eng C, Smith DP, Mulligan LM, et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995; 10: 509-13.
179. Pigny P, Bauters C, Wemeau JL, et al. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 1999; 84: 1700-4.
180. Da Silva AM, Maciel RM, Da Silva MR, et al. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 2004; 88: 5438-43.
181. Eng C, Mulligan LM, Healey CS, et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 1996; 56: 2167-70.
182. Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the RET protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996; 81: 1619-22.
183. Bugalho MJ, Frade JP, Santos JR, Limbert E, Sobrinho L. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine rich domain. Eur J Endocrinol 1997; 136: 423-6.
184. Scurini C, Quadro L, Fattoruso O, et al. Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 1998; 137: 51-7.
185. Uchino S, Noguchi S, Yamashita H, et al. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Jpn J Cancer Res 1999; 90: 1231-7.
186. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 347-51.
187. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-75.
188. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005; 65: 7591-5.
189. Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-73.
190. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29: 3085-96.
191. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-13.
192. Santarpia L, Qi Y, Stemke-Hale K, Wang B, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 2012. [Epub ahead of print]
193. Mologni L. Development of RET kinase inhibitors for targeted cancer therapy. Curr Med Chem 2011; 18: 162-75.
194. Zuercher WJ, Turunen BJ, Lackey KE. Current review of small molecule Ret kinase inhibitors. Mini Rev Med Chem 2010; 10: 138-46.
195. Boly R, Gras T, Lamkami T, et al. Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int J Oncol 2011; 38: 833-42.
196. Cohen MS, Hussain HB, Moley JF. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 2002; 132: 960-6.
197. Cassinelli G, Lanzi C, Pensa T, et al. Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin. Biochem Pharmacol 2000; 59: 1539-47.
198. Taniguchi M, Uehara Y, Matsuyama M, Takahashi M. Inhibition of ret tyrosine kinase activity by herbimycin A. Biochem Biophys Res Commun 1993; 195: 208-14.
199. Samadi AK, Mukerji R, Shah A, Timmermann BN, Cohen MS. A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo. Surgery 2010; 148: 1228-36.
200. Alfano L, Guida T, Provitera L, et al. RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block. J Clin Endocrinol Metab 2010; 95: 3552-7.
201. Plaza-Menacho I, de Groot JW, Links T, Plukker J, Eggen BJ, Hofstra R. Re: "Inhibition of medullary thyroid carcinoma (MTC) cell proliferation and RET phosphorylation by tyrosine kinase inhibitors". Surgery 2004; 135: 240-1.
202. Marsee DK, Venkateswaran A, Tao H, et al. Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. J Biol Chem 2004; 279: 43990-7.
203. Plaza-Menacho I, Mologni L, Sala E, et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 2007; 282: 29230-40.
204. Skinner MA, Safford SD, Freemerman AJ. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Res 2003; 23: 3601-6.
205. Pong K, Xu RY, Beck KD, Zhang TJ, Louis JC. Inhibition of glial cell line-derived neurotrophic factor induced intracellular activity by K-252b on dopaminergic neurons. J Neurochem 1997; 69: 986-94.
206. Strock CJ, Park JI, Rosen M, et al. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block me dullary thyroid carcinoma cell growth. Cancer Res 2003; 63: 5559-63.
207. Carlomagno F, Vitagliano D, Guida T, et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002; 62: 1077-82.
208. Carlomagno F, Vitagliano D, Guida T, et al. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin. Endocrinol Metab 2003, 88: 1897-902.
209. Knowles PP, Murray-Rust J, Kjaer S, et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 2006; 281: 33577-87.
210. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004; 23: 6056-63.
211. Liu Y, Bishop A, Witucki L, et al. M. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 1999; 6: 671-8.
212. Carniti C, Perego C, Mondellini P, Pierotti MA, Bongarzone I. PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting. Cancer Res 2003; 63: 2234-43.
213. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis, and tumour growth following oral administration. Cancer Res 2002; 62: 4645-55.
214. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research 2002; 62: 7284-90.
215. Johanson V, Ahlman H, Bernhardt P, et al. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinasedriven tumorigenesis. Endocrine-Related Cancer 2007; 14: 433-44.
216. Vidal M, Wells S, Ryan A, Cagan R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Research 2005; 65: 3538-41.
217. Bianco R, Rosa R, Damiano V, et al. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clinical Cancer Research 2008; 14: 5069-80.
218. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clinical Cancer Research 2003; 9: 1546-56.
219. Mologni L, Sala E, Riva B, et al. Expression, purification, and inhibition of human RET tyrosine kinase. Protein Expr Purif 2005; 41: 177-85.
220. Sun L, Tran N, Liang C, et al. Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem 1999; 42: 5120-30.
221. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6: 734-45.
222. Lanzi C, Cassinelli G, Pensa T, et al. Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer 2000; 85: 384-90.
223. Rizzi E, Cassinelli G, Dallavalle S, et al. Synthesis and RET protein kinase inhibitory activity of 3-arylureidobenzylidene-indolin-2-ones. Bioorg Med Chem Lett 2007; 17: 3962-8.
224. Lanzi C, Cassinelli G, Cuccuru G, et al. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci 2003; 60: 1449-59.
225. Cuccuru G, Lanzi C, Cassinelli G, et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 2004; 96: 1006-14.
226. Mologni L, Sala E, Cazzaniga S, et al. Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol 2006; 37: 199-212.
227. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-96.
228. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 2008; 37: 511-24.
229. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91: 4070-6.
230. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
231. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98: 326-34.
232. Akeno-Stuart N, Croyle M, Knauf JA, et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 2007; 67: 6956-64.
233. LaMontagne KR, Butler J, Borowski VB, et al. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. Angiogenesis 2009; 12: 287-96.
234. Wang D, Tang F, Wang S, Jiang Z, Zhang L. Preclinical antiangiogenesis and anti-tumor activity of SIM010603, an oral, multitargets receptor tyrosine kinases inhibitor. Cancer Chemother Pharmacol 2012; 69: 173-83.
235. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658-68.
236. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006; 66: 8715-21.
237. Clemens GR, Schroeder RE, Magness SH, et al. Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol 2009; 85: 130-6.
238. Cui JJ. Inhibitors targeting hepatocyte growth factor receptors and their potential therapeutic applications. Expert Opin Ther Pat 2007; 17: 1035-45.
239. Zhang Y, Guessous F, Kofman A, Schiff D, Abounader R. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010; 13: 112-21.
240. Verbeek HH, Alves MM, de Groot JW, et al. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 2011; 96: E991-5.
241. Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ. Danusertib, an aurora kinase inhibitor. Expert Opin Investig Drugs 2012; 21: 383-93.
242. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262-7.
243. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drugresistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102: 11011-6.
244. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-32.
245. Brandt W, Mologni L, Preu L, Lemcke T, Gambacorti-Passerini C, Kunick C. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. Eur J Med Chem 2010; 45: 2919-27.
246. Cincinelli R, Cassinelli G, Dallavalle S, et al. Synthesis, modeling, and RET protein kinase inhibitory activity of 3-and 4-substituted beta-carbolin-1-ones. J Med Chem 2008; 51: 7777-87.
247. Shih KC, Shiau CW, Chen TS, et al. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors. Bioorg Med Chem Lett 2011; 21: 4490-7.
248. Kunnimalaiyaan M, Ndiaye M, Chen H. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 2006; 140: 1009-14.
249. Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 2010, 116: 2974-83.
250. Ludwig L, Kessler H, Wagner M, et al. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RETinduced transformation. Cancer Res 2001; 61: 4526-35.
251. Croyle M, Akeno N, Knauf JA, et al. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res 2008; 68: 4183-91.
252. Cakir M, Grossman AB. Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology 2009; 90: 323-48.
253. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006; 27: 535-60.
254. Iervolino A, Iuliano R, Trapasso F, Viglietto, et al. The receptortype protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. Cancer Res 2006; 66: 6280-7.
255. Cerchia L, Duconge F, Pestourie C, et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 2005; 3: e123.
256. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther 2006; 13: 464-77.
257. de Martimprey H, Bertrand JR, Fusco A et al. siRNA nanoformulation against the ret PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res 2008; 36: e2.
258. Koga K, Hattori Y, Komori M, et al. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis. Cancer Sci 2010; 101: 941-7.
259. Drosten M, Stiewe T, Pützer BM. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum Gene Ther 2003; 14: 971-82.
260. Parthasarathy R, Cote GJ, Gagel RF. Hammerhead ribozymemediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res 1999; 59: 3911-4.
261. Messina M, Robinson BG: Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 2007; 3: 290-301.
262. Cerchia L, Libri D, Carlomagno MS, de Franciscis V. The soluble ectodomain of RetC634Y inhibits both the wild-type and the constitutively active Ret. Biochem J 2003; 372: 897-903.
263. Yano L, Shimura M, Taniguchi M, et al. Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase. Hum Gene Ther 2000; 11: 995-1004.
264. Stein R, Goldenberg DM. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther 2004; 3: 1559-64.
265. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
266. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
267. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebocontrolled trial. Lancet Oncol 2009; 10: 25-34.
268. Brose MS, Nutting CM, Sherman SI, et al. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011; 11: 349.
269. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
270. Patil S, Figlin RA, Hutson TE, et al. Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-β. Br J Cancer 2012; 106: 1587-90.
271. Younus J, Verma S, Franek J, Coakley N, Sacroma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. Curr Oncol 2010; 17: 4-10.
272. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-13.
273. Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial. J Clin Oncol 2012; 30: 2070-8.
274. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011; 29: 2660-6.